The Department of Health – Abu Dhabi (DoH) has made a major advancement in healthcare by granting early access to WINREVAIR, a groundbreaking medication for patients with pulmonary arterial hypertension (PAH). This makes Abu Dhabi the first in the region to offer this innovative treatment.
WINREVAIR, developed by global biopharmaceutical leader MSD, can be self-administered by patients or caregivers under medical supervision, with a subcutaneous injection every three weeks. The medication helps to widen the pulmonary blood vessels, improving blood flow and relieving pressure on the cardiovascular system.
When used alongside standard treatments, it reduces mortality risks and can potentially extend life expectancy by more than a decade for low to moderate risk patients. Clinical trials show that WINREVAIR reduces the risk of both fatal and non-fatal worsening events by 84%.
The medication has been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). WINREVAIR targets and blocks specific signaling pathways that cause excessive cell proliferation in the pulmonary blood vessels, alleviating vascular narrowing.
Globally, PAH affects between 15 and 60 people per million, with women accounting for 70 to 80 percent of cases. The condition is most common in individuals aged 50 to 65.-WAM
